소 헬스케어 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the cattle healthcare market size is projected to expand from USD 8.91 billion in 2025 and USD 9.42 billion in 2026 to USD 12.43 billion by 2030, registering a CAGR of 5.71% between 2026 to 2030.

This report is Segmented by Product Type [Therapeutics (Vaccines and More), Diagnostics (Immunodiagnostics and More)], Disease (BRD, Mastitis, BVD, FMD, and More), End User (Dairy Farms, Beef Feedlots, Breeding Operations, Veterinary Clinics, Government Institutes, Ranches), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Market Forecasts are Provided in Terms of Value (USD).

Global Cattle Healthcare Market Trends and Insights

Surging Global Consumption of Animal Protein

Beef intake in Asia-Pacific rose 3.2% in 2025, far above the world average, reinforcing the need to lift per-animal productivity through preventive health protocols . Middle Eastern buyers now demand veterinary certificates that exceed OIE baselines, obliging exporters to invest in rapid diagnostics and traceability. India added 2.1 million milking cows in 2025, yet subclinical mastitis still erodes yields by up to 20%, creating clear headroom for point-of-care immunodiagnostics. Urban Chinese consumers are paying 12% more for milk labeled low in antibiotic residues, nudging cooperatives toward prophylactic biologics. Altogether, demand growth is less about herd expansion and more about squeezing higher, residue-free output from existing cattle through precision health investments.

Expansion of Preventive-Care Subsidies

USDA matching grants worth USD 180 million in 2025 covered automated vaccination, surveillance networks, and on-farm biosecurity upgrades, lowering producer payback periods to under two years. Common Agricultural Policy payments now reimburse up to 60% of the cost of integrated herd-health plans that meet animal-welfare and methane targets, effectively bundling climate goals with disease prevention. Brazil piloted a 40% vaccine subsidy for foot-and-mouth disease in transitioning states, spiking short-term biologics demand before the program sunsets. Once producers experience lower morbidity and cull losses under subsidized regimes, they rarely revert, creating a ratchet effect that locks in structural demand for vaccines and diagnostics.

Cold-Chain & Formulation Costs for Next-Gen Biologics

mRNA products demand -20 °C to -70 °C storage, yet majority of distributors in India and in sub-Saharan Africa lacked ultra-cold equipment in 2025. Spoilage reached 18% in Southeast Asia, forcing manufacturers to overship by up to 25% and lifting landed costs. Ceva reported that lyophilized mRNA prototypes last six months at room temperature but raise per-dose cost by 35%, a trade-off that limits adoption in price-sensitive areas. The result is a two-tier cattle healthcare market where advanced biologics stay locked in temperate, well-capitalized regions while emerging markets rely on older, less effective options.

Other drivers and restraints analyzed in the detailed report include:

1. Adoption of AI-Based Wearables
2. mRNA & Nanoparticle Vaccine Breakthroughs
3. Acute Shortage of Large-Animal Veterinarians

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Therapeutics maintained an 83.1% share of the cattle healthcare market in 2025, reflecting enduring reliance on vaccines, parasiticides, and anti-infectives that underpin basic biosecurity. Diagnostics, however, are forecast to grow 7.22% annually to 2031 as point-of-care PCR devices and on-farm biosensors compress result times to under 30 minutes. Molecular platforms captured a significant share of diagnostic revenue in 2025, buoyed by Neogen's USDA-approved handheld BVD detector priced at USD 4,200. Immunodiagnostics still dominate unit volumes, yet growth slows in saturated developed markets. Within therapeutics, vaccine demand outperforms anti-infectives as retailers and regulators clamp down on antibiotic use.

The tilt toward diagnostics underscores a strategic shift: preventing outbreaks delivers higher returns than treating sick animals, particularly as antimicrobial resistance attracts policy scrutiny. Mobile ultrasound and rapid chemistries remain niche but gain traction in breeding herds where early pregnancy confirmation tightens calving intervals. As uptake widens, diagnostics are set to boost the cattle healthcare market size for ancillary data-analytics services that benchmark herd performance.

Geography Analysis

North America held 41.2% of 2025 revenue as U.S. mega-dairies and feedlots invested in robotics, AI-based monitoring and proprietary biologics to hit retailer sustainability metrics. Canada's supply-managed dairy sector reinvested an average CAD 142 (USD 105) per cow in preventive care, 18% above the continental mean. Mexican feedlot expansion, buoyed by foreign capital, boosts respiratory vaccine sales, although counterfeit therapeutics and regulatory gaps temper growth.

Asia-Pacific rides a 6.98% CAGR as India's 303 million-head herd digitizes under National Livestock Mission subsidies, and China targets half of milk output from 1,000-plus-cow dairies by 2030. Japan and South Korea post world-leading per-head spend due to strict residue standards, while Australia's export-oriented graziers demand tick and vector vaccines for disease-free status. Southeast Asian cold-chain limitations restrain uptake of next-gen biologics, keeping older killed vaccines in rotation.

Europe accounts for a significant share of the cattle healthcare market, with antibiotic-reduction policies driving vaccine substitution and alternative therapies. German and French herds invest heavily in diagnostics that document low-residue status for premium retailers. South America leverages Brazil's 224 million-head herd yet sees cyclical demand swings tied to antigen tariffs and credit access. The Middle East and Africa remain smallest by value; however, GCC climate-controlled dairies and sub-Saharan disease-eradication campaigns are niche engines of higher-margin biologics demand.

1. AgriLabs
2. Biogenesis Bago
3. Boehringer Ingelheim Animal Health GmbH
4. Ceva Sante Animale
5. Dechra Pharmaceuticals
6. Elanco Animal Health Inc.
7. Hester Biosciences Ltd.
8. Huvepharma Inc.
9. IDEXX
10. Indian Immunologicals
11. Jinyu Bio-Technology Co.
12. Merck Animal Health (MSD)
13. Neogen Corp.
14. Norbrook Laboratories Ltd.
15. Ourofino Saude Animal SA
16. Phibro Animal Health
17. Tianjin Ringpu Bio-Pharma
18. Vetoquinol
19. Virbac
20. Zoetis
21. Zydus Animal Health & Investments Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Surging Global Consumption Of Animal Protein
  • 4.2.2 Expansion Of Preventive-Care Subsidies (US & EU)
  • 4.2.3 Adoption Of AI-Based Wearables for Early-Stage Disease Detection
  • 4.2.4 mRNA & Nanoparticle Vaccine Breakthroughs
  • 4.2.5 Carbon-Credit Premiums for Low-Methane Herds
  • 4.2.6 Blockchain-Verified Provenance Schemes Boosting Herd-Health Spend
• 4.3 Market Restraints
  • 4.3.1 Cold-Chain & Formulation Costs for Next-Gen Biologics
  • 4.3.2 Acute Shortage of Large-Animal Veterinarians
  • 4.3.3 Producer Push-Back on Data Ownership & Interoperability
  • 4.3.4 Tariff Volatility on Key Antigen Inputs
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Therapeutics
    • 5.1.1.1 Vaccines
    • 5.1.1.2 Parasiticides
    • 5.1.1.3 Anti-infectives
    • 5.1.1.4 Anti-inflammatories
    • 5.1.1.5 Medical Feed Additives
    • 5.1.1.6 Other Therapeutics
  • 5.1.2 Diagnostics
    • 5.1.2.1 Immunodiagnostics
    • 5.1.2.2 Molecular Diagnostics
    • 5.1.2.3 Diagnostic Imaging
    • 5.1.2.4 Point-of-Care Devices & Biosensors
    • 5.1.2.5 Clinical Chemistry
    • 5.1.2.6 Other Diagnostics
• 5.2 By Disease
  • 5.2.1 Bovine Respiratory Disease (BRD)
  • 5.2.2 Mastitis
  • 5.2.3 Bovine Viral Diarrhoea (BVD)
  • 5.2.4 Foot & Mouth Disease (FMD)
  • 5.2.5 Parasitic Infestations
  • 5.2.6 Metabolic & Reproductive Disorders
  • 5.2.7 Lumpy Skin & Other Vector-borne
• 5.3 By End User
  • 5.3.1 Dairy Farms
  • 5.3.2 Beef Feedlots
  • 5.3.3 Breeding Operations
  • 5.3.4 Veterinary Hospitals & Clinics
  • 5.3.5 Government & Research Institutes
  • 5.3.6 Ranches
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 India
    • 5.4.3.3 Japan
    • 5.4.3.4 South Korea
    • 5.4.3.5 Australia
    • 5.4.3.6 Rest of APAC
  • 5.4.4 Middle East & Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of MEA
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 AgriLabs
  • 6.3.2 Biogenesis Bago
  • 6.3.3 Boehringer Ingelheim Animal Health GmbH
  • 6.3.4 Ceva Sante Animale
  • 6.3.5 Dechra Pharmaceuticals PLC
  • 6.3.6 Elanco Animal Health Inc.
  • 6.3.7 Hester Biosciences Ltd.
  • 6.3.8 Huvepharma Inc.
  • 6.3.9 IDEXX Laboratories Inc.
  • 6.3.10 Indian Immunologicals Ltd.
  • 6.3.11 Jinyu Bio-Technology Co.
  • 6.3.12 Merck Animal Health (MSD)
  • 6.3.13 Neogen Corp.
  • 6.3.14 Norbrook Laboratories Ltd.
  • 6.3.15 Ourofino Saude Animal SA
  • 6.3.16 Phibro Animal Health Corp.
  • 6.3.17 Tianjin Ringpu Bio-Pharma
  • 6.3.18 Vetoquinol SA
  • 6.3.19 Virbac SA
  • 6.3.20 Zoetis Inc.
  • 6.3.21 Zydus Animal Health & Investments Ltd.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment